Tag Archives: Federal Circuit

Aventis v. Hospira – How to Meet the Therasense Standards

Posted on April 10, 2012 by Warren Woessner

On April 9, 2012, The Fed. Cir. affirmed a holding by the district court that rendered two (then) Sanofi add-on patents on infusion vehicles for docetaxel unenforceable due to inequitable conduct. The inventors, particularly inventor/project manager Fabre, were found to have … Continue reading →

Posted in Inequitable Conduct/Rule 56 | Tagged , , , , , | 2 Comments

Mayo v. Prometheus – A European View

Posted on March 29, 2012 by Warren Woessner

A Guest Post from Paul Cole, European Patent Attorney, Lucas & Co; Professor of IP law, Bournemouth University. Is a claim to an assay patent-eligible when all its features are known save for how it should be interpreted? The interpretation … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | 3 Comments

Supreme Court Remands In Myriad Appeal

Posted on March 26, 2012 by Warren Woessner

Today, as predicted by many commentators, the Supreme Court set aside the ruling by the Fed. Cir. that claims to isolated DNA sequences that are the BRCA 1 or 2 gene, or fragments thereof, are patentable subject matter. The Supreme … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | 1 Comment

Supreme Court Reverses In Prometheus v. Mayo!

Posted on March 20, 2012 by Warren Woessner

In a decision dated March 20, 2012, Justice Breyer writing for a unanimous court, held that claims to administering a drug, followed by measuring the levels of metabolites of the drug, in order to optimize the amount administered, are not patent … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | 8 Comments